TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 5440547

Group type: EXPERIMENTAL
Intervention: External pressure between 5 and 15 mm. Hg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: External pressure above 15 mm. Hg
Number of subjects: 9
Study: 30520405

Group type: EXPERIMENTAL
Intervention: Palliative care
Number of subjects: 351

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Palliative care stigma
Number of subjects: 351
Study: 29718430

Group type: EXPERIMENTAL
Intervention: +LPS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: +BCAA
Number of subjects: 20
Study: 26897454

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention (HLI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 160
Study: 25252600

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard PCI (Control)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups (including Bivalirudin anticoagulation and thrombus aspiration)
Number of subjects: 240
Study: 22805498

Group type: EXPERIMENTAL
Intervention: 250,000 IU of cholecalciferol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21061834

Group type: EXPERIMENTAL
Intervention: Olmesartan (40 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Irbesartan (300 mg/day)
Number of subjects: 34
Study: 17376712

Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 0.14% calcium hydroxide
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: polymyxin B
Number of subjects: 98

Group type: COMPARATOR
Intervention: saline solution
Number of subjects: 98

Group type: COMPARATOR
Intervention: negative control (no endotoxin)
Number of subjects: 98
Study: 16329464

Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA (3 g/day)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA (3 g/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12410740

Group type: EXPERIMENTAL
Intervention: Nocturia (mean of twice or more/night)
Number of subjects: 4721

Group type: EXPERIMENTAL
Intervention: Age, poor health status, and use of medication
Number of subjects: 4721

Group type: EXPERIMENTAL
Intervention: General practitioners' routine checks
Number of subjects: 4721
Study: 10421262

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy at a total dose of 60 gray
Number of subjects: 728

Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 728
Study: 7669462

Group type: EXPERIMENTAL
Intervention: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml with the addition of morphine 5 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Interscalene brachial plexus block with 0.5% bupivacaine and adrenaline 1/200,000 40 ml alone
Number of subjects: 40
Study: 2401752

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg) administered after food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine (250 mg) administered after antacid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ticlopidine (250 mg) administered in fasting conditions
Number of subjects: 0
Study: 7434079

Group type: EXPERIMENTAL
Intervention: Quinacrine (100 mg t.i.d. for 5 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Metronidazole (200 mg t.i.d. for 7 days)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Metronidazole (2 gm single dose)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 gm single dose)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ornidazole (2 gm single dose)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 6134959

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg IM
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg IM
Number of subjects: 117

Group type: COMPARATOR
Intervention: Spectinomycin 2 g IM
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Spectinomycin
Number of subjects: 117
Study: 31059947

Group type: EXPERIMENTAL
Intervention: Hisense computer-assisted surgery (CAS) system
Number of subjects: 104

Group type: COMPARATOR
Intervention: Computed tomography (CT) group
Number of subjects: 104
Study: 29293361

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 80
Study: 26597368

Group type: EXPERIMENTAL
Intervention: PHP‐Mel
Number of subjects: 93

Group type: COMPARATOR
Intervention: BAC
Number of subjects: 93
Study: 23639952

Group type: EXPERIMENTAL
Intervention: Group music therapy (12 sessions, two 30-min sessions per week for 6 weeks)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Group music therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 22495183

Group type: EXPERIMENTAL
Intervention: Oxycodone 5 mg/70 kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone 20 mg/70 kg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oxycodone (daily administration)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oxycodone (intermittent administration)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (daily administration)
Number of subjects: 10
Study: 19793397

Group type: EXPERIMENTAL
Intervention: Posterior cruciate retaining total knee arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posterior stabilized total knee arthroplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality of life measured by SF-36
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physician reported functional status and range of motion measured by Knee Society Clinical Rating System (KSS)
Number of subjects: 0
Study: 17984150

Group type: EXPERIMENTAL
Intervention: Group physical activity
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Increased-intensity physical activity
Number of subjects: 29

Group type: COMPARATOR
Intervention: Social activity
Number of subjects: 29
Study: 16416004

Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone for 1 month followed by 5 months of continuous treatment with interferon-alpha (treatment group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha combined with thymosin-alpha1 for 1 month followed by 5 months of continuous treatment with interferon-alpha and thymosin-alpha1 (treatment group B)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no antiviral drug after lamivudine withdrawal)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone or combined with thymosin-alpha1
Number of subjects: 66
Study: 12432287

Group type: EXPERIMENTAL
Intervention: Biofeedback intervention
Number of subjects: 118
Study: 10461814

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 21

Group type: COMPARATOR
Intervention: Coordination training
Number of subjects: 21
Study: 7554545

Group type: EXPERIMENTAL
Intervention: Isradipine (5 mg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fosinopril (20 mg)
Number of subjects: 17
Study: 1685651

Group type: EXPERIMENTAL
Intervention: Ozone-treated blood
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unprocessed blood (Control)
Number of subjects: 10
Study: 7469773

Group type: EXPERIMENTAL
Intervention: Open abdominal paracentesis and lavage
Number of subjects: 210

Group type: COMPARATOR
Intervention: Percutaneous abdominal paracentesis and lavage
Number of subjects: 210
Study: 31177984

Group type: EXPERIMENTAL
Intervention: Thalamic location of intracerebral hemorrhage
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Posterior limb internal capsule involvement
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Globus pallidus/putamen involvement
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Anterior limb internal capsule involvement
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Caudate location
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Anterior limb internal capsule lesions
Number of subjects: 467
Study: 27914817

Group type: EXPERIMENTAL
Intervention: Controller medicine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Quick relief medicine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Spacer
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Parental help with medications
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Inhaler technique
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Presence of medications
Number of subjects: 175
Study: 26435363

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT) with methyl aminolevulinate (MAL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT) with methyl aminolevulinate (MAL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daylight photodynamic therapy (DL‐PDT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional photodynamic therapy (c‐PDT)
Number of subjects: 100
Study: 23230105

Group type: EXPERIMENTAL
Intervention: 7-11 Synch (MGA)
Number of subjects: 477

Group type: COMPARATOR
Intervention: 7-11 CIDR
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: 7-11 Synch (with GnRH)
Number of subjects: 477

Group type: COMPARATOR
Intervention: 7 Synch (without GnRH)
Number of subjects: 477
Study: 21862727

Group type: EXPERIMENTAL
Intervention: R-leg (exercise with restricted blood flow)
Number of subjects: 2

Group type: COMPARATOR
Intervention: NR-leg (exercise with normal blood flow)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cultured human myotubes with AICAR stimulation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: AICAR combined with norepinephrine
Number of subjects: 2
Study: 19608845

Group type: EXPERIMENTAL
Intervention: Single injection (Group S): 30 mL of mepivacaine 1.5% injected posterior to the axillary artery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triple injections (Group T): 10 mL of mepivacaine 1.5% injected on the posterior, medial, and lateral aspects of the axillary artery
Number of subjects: 100
Study: 16448828

Group type: EXPERIMENTAL
Intervention: TTM-based counselling in physiotherapy (10 min counselling prior to each of 10 sessions of physiotherapy)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo ultrasound treatment (inactivated device, 10 sessions of physiotherapy of 20 min each)
Number of subjects: 170
Study: 15459167

Group type: EXPERIMENTAL
Intervention: CO2 (group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Normal saline (group B)
Number of subjects: 74
Study: 12861170

Group type: EXPERIMENTAL
Intervention: Early ECV (34-36 weeks gestation)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Delayed ECV (37-38 weeks gestation)
Number of subjects: 233
Study: 9928781

Group type: EXPERIMENTAL
Intervention: Pain diary intervention
Number of subjects: 159
Study: 7560617

Group type: EXPERIMENTAL
Intervention: Captopril therapy
Number of subjects: 0
Study: 2286709

Group type: EXPERIMENTAL
Intervention: Haloperidol (fixed doses to achieve plasma levels above and below 18 ng/ml)
Number of subjects: 25
Study: 7028259

Group type: EXPERIMENTAL
Intervention: Immediate CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Initial low-dose single-agent CCNU (CAMP postponed)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Immediate CAMP
Number of subjects: 72

Group type: COMPARATOR
Intervention: Postponed CAMP
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Quality of life measures
Number of subjects: 72
Study: 31998998

Group type: EXPERIMENTAL
Intervention: Concentration of Benefit index (Cb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expected treatment outcomes with knowledge of covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parametric and semiparametric estimators
Number of subjects: 0
Study: 30176834

Group type: EXPERIMENTAL
Intervention: 30-min vigorous-intensity aerobic exercise session 24 hours prior to each anthracycline treatment
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Prepared diet reduced to 50% of caloric needs for 48 hours prior to each anthracycline treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual cancer care
Number of subjects: 56
Study: 28139564

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meloxicam
Number of subjects: 40
Study: 24508349

Group type: EXPERIMENTAL
Intervention: Elevated glucose (>7.8 mmol/L)
Number of subjects: 3383
Study: 22420417

Group type: EXPERIMENTAL
Intervention: SoS letter only
Number of subjects: 139356

Group type: EXPERIMENTAL
Intervention: SoS letter and SoS brochure
Number of subjects: 139356

Group type: COMPARATOR
Intervention: SoS brochure only
Number of subjects: 139356
Study: 19947986

Group type: EXPERIMENTAL
Intervention: Increased nocturnal oxygen flow rate (1 L more oxygen)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Daytime oxygen flow rate
Number of subjects: 38
Study: 18762517

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cooling treatment
Number of subjects: 0
Study: 16046725

Group type: EXPERIMENTAL
Intervention: Iron intervention (specifics not provided)
Number of subjects: 9
Study: 12035957

Group type: EXPERIMENTAL
Intervention: 30mg ketorolac
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard anaesthetic and surgical technique
Number of subjects: 65
Study: 10901709

Group type: EXPERIMENTAL
Intervention: Ifetroban (3 mg/kg in rats)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ifetroban (1 mg/kg in dogs)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ifetroban (1 mg/kg in monkeys)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ifetroban (50 mg in humans)
Number of subjects: 4
Study: 8890312

Group type: EXPERIMENTAL
Intervention: Teeth clenching
Number of subjects: 0
Study: 1900663

Group type: EXPERIMENTAL
Intervention: Cefoxitin and doxycycline
Number of subjects: 148

Group type: COMPARATOR
Intervention: Clindamycin and tobramycin
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 148
Study: 6830051

Group type: EXPERIMENTAL
Intervention: 0.6 ppm sulfur dioxide (SO2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.4 ppm sulfur dioxide (SO2)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.2 ppm sulfur dioxide (SO2)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (0 ppm sulfur dioxide)
Number of subjects: 23
Study: 31465443

Group type: EXPERIMENTAL
Intervention: Affect Regulation Training (ART)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Waitlist Control (WLC)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Condition controlling for common factors (CFC)
Number of subjects: 218
Study: 29499343

Group type: EXPERIMENTAL
Intervention: Probabilistic Food Choice Questionnaire (PFCQ)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Probabilistic Monetary Choice Questionnaire (PMCQ)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Delay discounting (DD) tasks
Number of subjects: 110
Study: 25953002

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3D mChoi criteria
Number of subjects: 48

Group type: COMPARATOR
Intervention: 2D or 3D imaging criteria
Number of subjects: 48
Study: 24674976

Group type: EXPERIMENTAL
Intervention: Hypoxic training (FIO2 = 0.15)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Normoxic training (placebo)
Number of subjects: 17
Study: 21362642

Group type: EXPERIMENTAL
Intervention: Interactive journaling
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 183
Study: 20361918

Group type: EXPERIMENTAL
Intervention: Citalopram (n = 104)
Number of subjects: 198
Study: 18455841

Group type: EXPERIMENTAL
Intervention: HIV-1 rgp160
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15970392

Group type: EXPERIMENTAL
Intervention: Unsupported dieting
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Both dieting groups
Number of subjects: 3

Group type: COMPARATOR
Intervention: Commercially available weight loss group
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-dieting controls
Number of subjects: 3
Study: 12186623

Group type: EXPERIMENTAL
Intervention: One-week quadruple therapy (bismuth-based triple therapy plus a PPI or histamine receptor 2-blocker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Furazolidone-based triple therapy (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone-based triple therapy (levofloxacin or moxifloxacin plus an antibiotic and a PPI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ecabet sodium-based triple therapy (ecabet plus two antibiotics)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with a PPI and amoxycillin
Number of subjects: 0
Study: 16021868

Group type: EXPERIMENTAL
Intervention: Nevirapine-containing regimen
Number of subjects: 57

Group type: COMPARATOR
Intervention: Protease inhibitor (PI) regimen
Number of subjects: 57
Study: 8924308

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with EMLA cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrous oxide with intradermal lidocaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitrous oxide alone
Number of subjects: 60
Study: 7523772

Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg b.i.d.
Number of subjects: 693

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study: 3499015

Group type: EXPERIMENTAL
Intervention: BCG vaccinated children
Number of subjects: 1421

Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Tuberculin testing in vaccinated children
Number of subjects: 1421
Study: 30195044

Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ, Sφ)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: PTFJ morphological parameters (S, Sτ, Sυ)
Number of subjects: 408
Study: 26984864

Group type: EXPERIMENTAL
Intervention: Fluid status telemedicine alerts (intervention arm)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 1002
Study: 25273893

Group type: EXPERIMENTAL
Intervention: Active T-PEMF (one daily dose)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Active T-PEMF (two daily doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo T-PEMF (one daily dose)
Number of subjects: 65
Study: 24384592

Group type: EXPERIMENTAL
Intervention: Daily oral tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21451938

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 19936518

Group type: EXPERIMENTAL
Intervention: Wand computer-controlled local anesthesia application
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional anesthesia technique
Number of subjects: 16
Study: 17014550

Group type: EXPERIMENTAL
Intervention: High-volume haemofiltration (HVHF) at 6 L/h
Number of subjects: 33

Group type: COMPARATOR
Intervention: Continuous venovenous haemofiltration (CVVH) at 2 L/h
Number of subjects: 33
Study: 15257738

Group type: EXPERIMENTAL
Intervention: High brushing force (+/‐3.5 N)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low brushing force (+/‐1.5 N)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (Low brushing force)
Number of subjects: 35
Study: 11020900

Group type: EXPERIMENTAL
Intervention: Gabexate mesilate infusion at a dose of 100 mg/hr for 7 days
Number of subjects: 52
Study: 9540058

Group type: EXPERIMENTAL
Intervention: Oral tamoxifen (TAM) at doses of 40, 80 or 120 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgery, radiotherapy (4500-6000 cGy), and carboplatin (CBDCA; dose of 450-600 mg/m2)
Number of subjects: 40
Study: 7800587

Group type: EXPERIMENTAL
Intervention: Fish oil (12 grams daily, 3.6 g of EPA and DHA) for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Olive oil (12 grams daily) for 3 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fish oil (12 grams daily) for 6 weeks (in 9 patients)
Number of subjects: 20
Study: 3388151

Group type: EXPERIMENTAL
Intervention: Diltiazem (DTZ) 90 mg twice daily, increased to 180 mg if non-responders after 8 weeks
Number of subjects: 29

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCT) 25 mg once daily, increased to 50 mg if non-responders after 8 weeks
Number of subjects: 29
Study: 29311135

Group type: EXPERIMENTAL
Intervention: BMS‐823778 (single and multiple ascending doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS‐823778 in poor metabolizers (PMs) of CYP2C19
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS‐823778 in subjects with predicted CYP2C19 PM phenotype
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS‐823778 (overall safety profile)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BMS‐823778 (pharmacokinetics)
Number of subjects: 0
Study: 26805006

Group type: EXPERIMENTAL
Intervention: SRP with aPDT
Number of subjects: 90

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 90
Study: 25272034

Group type: EXPERIMENTAL
Intervention: Pylorus removal during subtotal stomach-preserving pancreaticoduodenectomy or pylorus-resecting pancreaticoduodenectomy
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Pylorus removal
Number of subjects: 2599

Group type: COMPARATOR
Intervention: Pylorus-preserving group
Number of subjects: 2599
Study: 22723267

Group type: EXPERIMENTAL
Intervention: rosiglitazone (RSG) 4 mg b.i.d
Number of subjects: 28

Group type: COMPARATOR
Intervention: matching placebo (PLC)
Number of subjects: 28